This Viewpoint presents the history of the Health Resources & Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limit...

Republicans aren't confident the Trump administration is taking a promised review seriously.

The US Food and Drug Administration (FDA) is at a crossroads. There is an urgent need to strengthen the integrity of drug approvals and rejections by diffusing the decision-making authority of individ...

On Super Bowl Sunday, the drug industry is trotting out lounging football stars, a shouting DJ Khaled, and the soothing tones of Enya.

With abortions still on the rise nationwide despite widespread bans, curtailing the use of pregnancy-terminating medication is a top priority for abortion opponents — and they’re frustrated that the T...

The proposal, coming ahead of the midterm elections, falls far short of President Donald Trump’s promises to deliver a replacement for the Affordable Care Act.

SAMHSA canceled up to $1.9 billion in grants without staff consultation, accelerating the mental health agency's deterioration under President Trump.

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.

At a STAT event, veteran drug regulator Richard Pazdur, who left the FDA last month after 26 years, said that politics and 'chaos' were damaging the agency.

YouTube video by Federal Reserve

Fewer standalone Rx plans in traditional Medicare raises questions about whether beneficiaries will have choices that align with health needs and budgets.

The state’s highest court ruled that two near-total state abortion bans violate the constitution.